US 12,077,580 B2
Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
Franco E. Di Padova, Basel (CH); Thomas Huber, Basel (CH); and Jean-Michel Rene Rondeau, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Apr. 30, 2020, as Appl. No. 16/862,776.
Application 16/862,776 is a division of application No. 15/906,446, filed on Feb. 27, 2018, granted, now 10,683,349.
Application 15/906,446 is a division of application No. 15/466,128, filed on Mar. 22, 2017, granted, now 9,938,342, issued on Apr. 10, 2018.
Application 15/466,128 is a division of application No. 14/859,872, filed on Sep. 21, 2015, granted, now 9,650,439, issued on May 16, 2017.
Application 14/859,872 is a division of application No. 14/174,942, filed on Feb. 7, 2014, granted, now 9,193,788, issued on Nov. 24, 2015.
Claims priority of provisional application 61/762,406, filed on Feb. 8, 2013.
Prior Publication US 2020/0299379 A1, Sep. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2299/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 7 Claims
 
1. A method of treating a neuroinflammatory disease in a subject in need thereof comprising: administering to said subject an effective amount of an IL-17A binding antibody or antigen-binding portion thereof, wherein said IL-17A binding antibody or antigen-binding portion thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL);
wherein:
a) said VH comprises the three Complementarity Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO:12, and said VL comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO: 43;
b) said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:3, and said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, and SEQ ID NO:11; or
c) said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, and SEQ ID NO:6; and
wherein said antibody or antigen-binding portion thereof inhibits proinflammatory cytokine release from astrocytes.